SCHEMBL4347175

SCHEMBL4347175

CCOc1ccc(CC(OC(C)C)C(=O)O)cc1NC(=O)COc1ccccc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.50
KMT2A Q03164 4/20 0.50
SMN1; SMN2 Q16637 3/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
POLB P06746 3/20 0.48
MAPT P10636 3/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
MAPK10 P53779 1/20 0.47
TRPM4 Q8TD43 3/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
STAT3 P40763 1/20 0.46
LMNA P02545 1/20 0.46
TDP1 Q9NUW8 2/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
SENP2 Q9HC62 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4329366 0.91 SMN1; SMN2 (0.53) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL4337069 0.86 PPARG (0.46) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL4328620 0.85 L3MBTL1 (0.48) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL4336526 0.83 PPARG (0.45) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL4337189 0.82 MAPT (0.52) MEN1KMT2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL4333407 0.81 PPARA (0.47) MEN1KMT2ASMN1; SMN2CYP2C19POLB
SCHEMBL4345878 0.80 PPARA (0.50) KMT2ACYP1A2CYP2C19CYP2C9KDM4E
SCHEMBL4347011 0.78 SMN1; SMN2 (0.39) MEN1KMT2ASMN1; SMN2LMNA
SCHEMBL4336608 0.77 PPARG (0.42) MEN1KMT2ASMN1; SMN2MAPTNPC1
SCHEMBL4331663 0.77 SMN1; SMN2 (0.50) MEN1KMT2ASMN1; SMN2POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-7544835-B2 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-09 US disclosed
US-20040102634-A1 Carboxylic acid derivative and salt thereof EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-05-27 US disclosed
EP-1380562-A1 CARBOXYLIC ACID DERIVATIVE AND SALT THEREOF Eisai Co., Ltd. (JP) 2004-01-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102634-A1 Carboxylic acid derivative and salt thereof GPR119, IRS1, SLC5A1 MEN1 4091/4885KMT2A 2774/4885SMN1; SMN2 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.